αB-crystallin expression in breast cancer is associated with brain metastasis

Background/objectives:The molecular chaperone αB-crystallin is expressed in estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 ‘triple-negative’ breast carcinomas and promotes brain and lung metastasis. We examined αB-crystallin expression in primary breast carcinomas with metastatic data to evaluate its association with prognosis and site-specific metastases.Methods:αB-crystallin gene (CRYAB) expression was examined using publically available global-gene expression data (n=855 breast tumors) with first site of distant metastasis information (‘855Met’). αB-crystallin protein expression was determined by immunohistochemistry using the clinically annotated British Columbia Cancer Agency (BCCA) tissue microarray (n=3,987 breast tumors). Kaplan–Meier and multivariable Cox regression analyses were used to evaluate the prognostic value of αB-crystallin. Multivariable logistic regression analysis was used to evaluate risks of αB-crystallin and other markers for site of metastasis.Results:In the 855Met data set, αB-crystallin gene (CRYAB) expression was an independent predictor of brain as the first distant site of relapse (hazards ratio, HR=1.2, (95% confidence interval, CI 1.0–1.4), P=0.021). In the BCCA series, αB-crystallin protein expression was an independent prognostic marker of poor breast cancer-specific survival (HR=1.3, (95% CI 1.1–1.6), P=0.014). Among patients with metastases, αB-crystallin was the strongest independent predictor of brain metastasis (odds ratio, OR=2.99 (95% CI 1.83–4.89), P<0.0001) and the only independent predictor of brain as the first site of distant metastasis (OR=3.15 (95% CI 1.43–6.95), P=0.005). αB-crystallin was also associated with worse survival (3.0 versus 4.7 months, P=0.007).Conclusions:αB-crystallin is a promising biomarker to identify breast cancer patients at high risk for early relapse in the brain, independent of estrogen receptor and human epidermal growth factor receptor-2 status.

[1]  X. Chen,et al.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. , 2011, The Journal of clinical investigation.

[2]  W. Gradishar,et al.  ERK-regulated αB-Crystallin Induction by Matrix Detachment Inhibits Anoikis and Promotes Lung Metastasis in vivo , 2015, Oncogene.

[3]  N. Lin,et al.  Sites of distant recurrence and clinical outcomes in patients with metastatic triple‐negative breast cancer , 2008, Cancer.

[4]  C. Miller,et al.  αB-Crystallin: A Novel Regulator of Breast Cancer Metastasis to the Brain , 2013, Clinical Cancer Research.

[5]  A. Stan,et al.  Predominance of the basal type and HER-2/neu type in brain metastasis from breast cancer , 2007, Modern Pathology.

[6]  L. Chin,et al.  Bcl2L12-mediated inhibition of effector caspase-3 and caspase-7 via distinct mechanisms in glioblastoma , 2008, Proceedings of the National Academy of Sciences.

[7]  Jason I. Herschkowitz,et al.  Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer , 2010, Breast Cancer Research.

[8]  E. Winer,et al.  Brain Metastases: The HER2 Paradigm , 2007, Clinical Cancer Research.

[9]  Charles M. Perou,et al.  Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse , 2011, Breast Cancer Research and Treatment.

[10]  Marta C Guadamillas,et al.  Overcoming anoikis – pathways to anchorage-independent growth in cancer , 2011, Journal of Cell Science.

[11]  K. Camphausen,et al.  Brain metastases as preventive and therapeutic targets , 2011, Nature Reviews Cancer.

[12]  G. Reddy,et al.  Emerging role for αB-crystallin as a therapeutic agent: pros and cons. , 2015, Current molecular medicine.

[13]  V. Cryns,et al.  Minireview: Basal-like breast cancer: from molecular profiles to targeted therapies. , 2011, Molecular endocrinology.

[14]  Karen Gelmon,et al.  Metastatic behavior of breast cancer subtypes. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  P. Tan,et al.  αB‐crystallin is a useful marker for triple negative and basal breast cancers , 2012, Histopathology.

[16]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[17]  E. Winer,et al.  CNS metastases in breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  S. Steinberg,et al.  Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain. , 2007, Cancer research.

[19]  Samuel Leung,et al.  Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype , 2008, Clinical Cancer Research.

[20]  W. Gerald,et al.  Genes that mediate breast cancer metastasis to the brain , 2009, Nature.

[21]  A. Rademaker,et al.  αB-crystallin is a novel predictor of resistance to neoadjuvant chemotherapy in breast cancer , 2008, Breast Cancer Research and Treatment.

[22]  H. Kang,et al.  αB-Crystallin is a Novel Oncoprotein Associated with Poor Prognosis in Breast Cancer , 2011, Journal of breast cancer.

[23]  A. Gown,et al.  Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma , 2004, Clinical Cancer Research.

[24]  H. Harputluoglu,et al.  Breast cancer subtypes and outcomes of central nervous system metastases. , 2011, Breast.

[25]  Andy J. Minn,et al.  Genes that mediate breast cancer metastasis to lung , 2005, Nature.

[26]  J. C. Wilkinson,et al.  The Small Heat Shock Protein αB-crystallin Is a Novel Inhibitor of TRAIL-induced Apoptosis That Suppresses the Activation of Caspase-3* , 2005, Journal of Biological Chemistry.

[27]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[28]  P. Mehlen,et al.  Human hsp27, Drosophila hsp27 and human alphaB‐crystallin expression‐mediated increase in glutathione is essential for the protective activity of these proteins against TNFalpha‐induced cell death. , 1996, The EMBO journal.

[29]  Joel S. Parker,et al.  Adjustment of systematic microarray data biases , 2004, Bioinform..

[30]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[31]  C. Perou,et al.  A survey of immunohistochemical biomarkers for basal-like breast cancer against a gene expression profile gold standard , 2013, Modern Pathology.

[32]  G. Hortobagyi,et al.  Incidence of brain metastases as a first site of recurrence among women with triple receptor-negative breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  T. Nielsen,et al.  Breast cancer subtypes and the risk of local and regional relapse. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[35]  Charles M. Perou,et al.  Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer , 2009, Journal of the National Cancer Institute.

[36]  F. Chen,et al.  The Small Heat Shock Protein αB-Crystallin Negatively Regulates Cytochrome c- and Caspase-8-dependent Activation of Caspase-3 by Inhibiting Its Autoproteolytic Maturation* , 2001, The Journal of Biological Chemistry.

[37]  Lang Li,et al.  Predicting early brain metastases based on clinicopathological factors and gene expression analysis in advanced HER2-positive breast cancer patients , 2015, Journal of Neuro-Oncology.

[38]  J. Moyano,et al.  AlphaB-crystallin: a novel marker of invasive basal-like and metaplastic breast carcinomas. , 2008, Annals of diagnostic pathology.

[39]  A. Nobel,et al.  Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  John W M Martens,et al.  Subtypes of breast cancer show preferential site of relapse. , 2008, Cancer research.

[41]  T. Nielsen,et al.  Basal and triple-negative breast cancers: impact on clinical decision-making and novel therapeutic options. , 2008, Clinical breast cancer.

[42]  Reddy Vs,et al.  Emerging role for αB-crystallin as a therapeutic agent: pros and cons. , 2015 .